Acadia Pharmaceuticals has secured a positive opinion from the Committee for Medicinal Products for Human Use recommending Daybu (trofinetide) for the treatment of neurobehavioural symptoms of Rett syndrome in adults and children aged five years and older. The recommendation followed a re-examination of an earlier negative opinion and moves the medicine to a European Commission decision that could make Daybu the first therapy specifically approved for this indication in the European Union.
Why Daybu’s restricted European indication changes the treatment claim more than the eligible population
The importance of the positive opinion lies less in a conventional regulatory reversal and more in how the treatment claim was reconstructed. Acadia Pharmaceuticals originally sought approval for the broader treatment of Rett syndrome in adults and children aged two years and older. The revised indication is limited to neurobehavioural symptoms and begins at five years of age, bringing the proposed use closer to the population and outcomes studied in the pivotal clinical programme.
That distinction resolves part of the mismatch that contributed to the initial rejection. The clinical evidence showed changes in behavioural, emotional and communication-related manifestations, but it did not establish that trofinetide treated every major component of Rett syndrome. The programme did not demonstrate effects on several serious features of the condition, including seizures, progressive mobility problems, respiratory abnormalities or scoliosis. Describing Daybu as a treatment for neurobehavioural symptoms therefore creates a more defensible relationship between the label and the endpoints that produced the positive results.
The narrower indication is not merely regulatory wording. It establishes the boundaries within which clinicians, payers and families will judge treatment success. Daybu is not being positioned in Europe as a cure, a gene-correcting intervention or a comprehensive treatment for Rett syndrome. It is being assessed as a medicine that may improve a defined group of symptoms such as repetitive hand movements, restlessness, mood disturbances, anxiety, sleep difficulties and communication problems.
This precision makes approval more achievable, but it may also require careful expectation management. Rett syndrome affects multiple organ systems and imposes substantial functional limitations that cannot be captured by one behavioural scale. A modest improvement in neurobehavioural symptoms may still be meaningful in a condition with no approved European treatment for those symptoms, although it should not be interpreted as evidence that the underlying genetic disorder has been corrected.
How the LAVENDER trial supports Daybu approval while leaving clinical effect size questions unresolved
The pivotal LAVENDER study was a 12-week, randomised, double-blind and placebo-controlled phase 3 trial involving 187 girls and young women aged five to 20 years. Participants received twice-daily trofinetide or placebo, with efficacy evaluated through both caregiver and clinician assessments.
The trial met its co-primary endpoints. The difference between trofinetide and placebo on the caregiver-completed Rett Syndrome Behaviour Questionnaire was 3.1 points in favour of trofinetide, while the difference on the clinician-rated Clinical Global Impression of Improvement scale was 0.3 points. The corresponding effect sizes were modest, but the direction of benefit was supported by two perspectives and remained broadly consistent across several subgroups.
That dual-endpoint design is an important strength because Rett syndrome can be difficult to assess through conventional clinical measures. Many affected individuals have limited speech, impaired purposeful hand use and substantial variation in symptom severity. Caregivers observe patients across daily environments, while clinicians provide a more standardised medical assessment. Agreement between those perspectives reduces, but does not eliminate, uncertainty around whether an observed change is meaningful.
The central limitation is the magnitude rather than the statistical validity of the effect. European regulators initially considered the improvements too small to establish a clinically meaningful benefit for the broad treatment of Rett syndrome. The re-examination did not transform those numerical results into larger effects. Instead, it concluded that the observed improvements could be relevant when judged within the narrower neurobehavioural indication and the context of a rare, severe disorder with limited treatment options.
The trial’s 12-week duration also leaves questions about durability. Open-label extension findings have suggested continued symptom improvement during treatment lasting up to 40 weeks, but an uncontrolled extension cannot separate a sustained pharmacological effect from changes in caregiver expectations, patient selection or the withdrawal of participants unable to tolerate therapy. Longer-term evidence will therefore remain important even after a European authorisation.
Generalisability is another unresolved issue. The pivotal study enrolled only female participants and excluded people older than 20 years. Rett syndrome predominantly affects females, but males can also have pathogenic MECP2 variants and may present with different clinical severity. The European indication includes adults without setting an upper age boundary, meaning that real-world practice will extend beyond the age range that generated the strongest controlled evidence.
Why gastrointestinal tolerability could determine whether Daybu becomes usable in routine Rett syndrome care
Daybu’s benefit-risk profile is shaped as much by tolerability as by efficacy. Diarrhoea, vomiting and weight loss are the most prominent adverse effects, and each carries greater practical significance in Rett syndrome than it might in a less medically complex population.
In the established safety profile, approximately 85% of treated patients experienced diarrhoea during clinical development, with persistent or recurring episodes affecting a substantial proportion despite treatment interruptions, dose changes or supportive management. Vomiting was also considerably more frequent with trofinetide than with placebo, while clinically relevant weight loss occurred in some patients.
These effects matter because feeding difficulties, constipation, reflux, impaired swallowing and poor weight gain are already common in Rett syndrome. Many patients depend on gastrostomy tubes or require intensive nutritional support. Adding a medicine that can produce frequent diarrhoea or vomiting may increase the workload placed on caregivers and multidisciplinary clinical teams, even when those adverse effects are classified as mild or moderate.
The European product is expected to be available as a 200 mg per millilitre oral solution administered twice daily, either by mouth or through a gastric tube. Weight-based dosing can require relatively large treatment volumes. That formulation allows flexible dosing and tube administration, but routine use will still depend on whether patients can remain on therapy long enough to experience a worthwhile benefit.
Specialist centres may need structured protocols covering nutritional status, hydration, gastrointestinal symptoms, weight changes and treatment persistence. The final European product information will determine the formal monitoring and dose-management requirements, but practical adoption will also depend on nursing resources, dietetic support and the ability of caregivers to manage side effects at home.
The commercial lesson from the United States is that formulation and tolerability can directly influence persistence. Acadia Pharmaceuticals has introduced a powder formulation in the United States partly to provide greater flexibility around dose volume and taste. The European recommendation currently concerns the oral solution, so the convenience advantages of the newer U.S. presentation should not be assumed to be available at launch.
What Daybu could add to European Rett syndrome management without replacing multidisciplinary care
European Rett syndrome care remains centred on symptom management rather than a single disease-specific medicine. Patients may require anti-seizure treatment, respiratory monitoring, nutritional intervention, physiotherapy, communication support, sleep management, orthopaedic care and assistance with mobility. Daybu would add a pharmacological option for neurobehavioural symptoms, but it would sit within that complex care model rather than replacing it.
This positioning could still be clinically important. Improvements in communication, mood, sleep or repetitive behaviours may affect daily functioning even when motor disability and other medical complications remain unchanged. Small average effects can conceal more substantial responses in selected patients, particularly within a heterogeneous genetic disorder where mutation type, disease severity and age may influence outcomes.
However, the absence of an established biomarker or fully understood mechanism makes patient selection difficult. Trofinetide is a synthetic analogue of a molecule derived from insulin-like growth factor 1, but precisely how it produces therapeutic effects in Rett syndrome remains unclear. Clinicians therefore lack a biological test that can identify likely responders before treatment begins.
European practice may consequently develop around individual therapeutic trials followed by structured reassessment. Specialists will need to determine whether changes observed after initiation are sufficiently consistent and meaningful to justify continued treatment. This will be particularly important when gastrointestinal burden is high or when improvements are subtle and difficult to distinguish from normal fluctuations in behaviour.
Daybu may also encourage more systematic measurement of neurobehavioural symptoms within specialist clinics. Greater use of validated scales and caregiver-reported outcomes could improve treatment monitoring, although those tools must be applied consistently to avoid interpreting every short-term behavioural change as a drug effect.
Why European reimbursement decisions may prove more demanding than the central marketing authorisation
A European Commission approval would provide one marketing authorisation across the European Union, but it would not create simultaneous or uniform patient access. Pricing, health technology assessment and reimbursement decisions are largely managed at national level, exposing Daybu to different evidentiary and economic standards across individual markets.
The restricted indication could help Acadia Pharmaceuticals by aligning the clinical claim with the evidence. It could also sharpen payer scrutiny because the debate will centre on whether modest neurobehavioural improvements justify the expected cost and treatment burden of a rare disease medicine.
Health technology assessment bodies are likely to examine the absolute size of the treatment effect, the durability of improvement, quality-of-life consequences, caregiver outcomes, discontinuation rates and the proportion of patients who experience a clinically noticeable response. A statistically significant average difference may not automatically satisfy agencies seeking evidence of meaningful functional improvement.
Long-term controlled data are limited, and withdrawal from extension studies complicates the assessment of sustained benefit. Real-world evidence will therefore become central to reimbursement negotiations and future reassessments. European registries could help establish treatment persistence, symptom trajectories, adverse-event management and the characteristics of patients most likely to benefit.
Access may initially concentrate in specialist Rett syndrome centres with the expertise to document baseline symptoms and monitor response. This could improve treatment governance but create geographic inequalities for families living far from recognised centres. The authorisation would remove the regulatory barrier, while national funding decisions and healthcare capacity would determine how quickly that opportunity becomes practical access.
How the positive CHMP opinion strengthens Acadia Pharmaceuticals’ strategy while preserving commercial risk
The CHMP recommendation supports Acadia Pharmaceuticals’ effort to turn Daybu into an international rare disease franchise rather than a predominantly U.S. product. Daybue generated approximately $101 million in U.S. net product sales during the first quarter of 2026, representing growth of about 20% from the corresponding period of 2025. Full-year guidance of $460 million to $490 million demonstrates that the treatment is already a significant commercial asset.
European expansion could provide a second major growth platform and diversify the revenue base. Acadia Pharmaceuticals has also been building regulatory pathways in Canada, Israel and Japan, creating a broader international commercial strategy around one of the few medicines to produce positive phase 3 evidence in Rett syndrome.
The positive opinion also avoids the immediate need to conduct another large pivotal trial before obtaining an initial European authorisation. That preserves time and capital, although the label is less expansive than the one secured in the United States and Canada. The age threshold excludes children between two and four years, while the symptom-specific wording limits the claims that can support promotion and reimbursement.
Investor sentiment reflected relief over the regulatory turnaround. Acadia Pharmaceuticals shares finished the latest session at $25.32, gaining approximately 6.8% after trading through a wide intraday range. The reaction indicates that the market views European approval as commercially relevant, but the absence of a larger share-price move also suggests that investors recognise the remaining reimbursement, launch and tolerability uncertainties.
Daybu’s first-mover position may be durable in the near term, although the Rett syndrome pipeline is advancing. Experimental gene therapies are being developed to address MECP2 dysfunction more directly, creating the possibility of future treatments with disease-modifying ambitions. Those programmes remain clinically and technically uncertain, especially because MECP2 expression must be tightly controlled, but they illustrate why Daybu cannot rely indefinitely on the absence of competition.
What clinicians and regulators will watch after the European Commission completes its Daybu review
The European Commission normally issues its decision within approximately 67 days of a positive CHMP opinion. Attention will then shift to the final summary of product characteristics, including dosing, adverse-effect management, monitoring requirements and any post-authorisation evidence commitments.
Treatment persistence will be among the most important real-world measures. A medicine with modest average efficacy must remain sufficiently tolerable for patients to continue taking it, while clinicians must be able to identify benefit without relying solely on subjective impressions. Discontinuation rates, dose modifications and gastrointestinal interventions will reveal whether clinical-trial management strategies can be reproduced across European healthcare systems.
The effectiveness of Daybu in older adults will also require close observation because controlled phase 3 data were generated in participants aged five to 20 years. Evidence will be needed on whether symptom improvements remain detectable across later disease stages and whether older patients experience different tolerability or nutritional risks.
Regulators and clinicians will also watch outcomes that were not established by the pivotal trial. An approval for neurobehavioural symptoms should not be interpreted as evidence of improved seizure control, mobility, respiratory function or cardiac outcomes. Future studies may explore broader effects, but the initial European use must remain anchored to the endpoints that supported the positive opinion.
The CHMP reversal therefore represents a meaningful but carefully bounded advance. Daybu could become the first approved European medicine targeting neurobehavioural symptoms of Rett syndrome, opening a new treatment option for a severely underserved population. Its long-term role will be decided not by approval alone, but by whether modest clinical improvements can be sustained, recognised by families and specialists, tolerated in medically complex patients and funded across fragmented European healthcare systems.
